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Abstract: Basal cell carcinoma (BCC) is the most common cancer in individuals with fair 
skin type (I–II) and steadily increasing in incidence (70% of skin malignancy). It is locally 
invasive but metastasis is usually very rare, with an estimated incidence of 0.0028%–0.55%. 
Conventional therapy is surgery, especially for the H region of the face and infiltrative 
lesions; in case of inoperable tumors, radiotherapy is a valid option. Recently, topical 
photodynamic therapy (PDT) has become an effective treatment in the management of 
superficial and small nodular BCC. PDT is a minimally invasive procedure that involves 
the administration of a photo-sensibilizing agent followed by irradiation at a pre-defined 
wavelength; this determines the creation of reactive oxygen species that specifically 
destroy target cells. The only major side effect is pain, reported by some patients during the 
irradiation. The high cure rate and excellent cosmetic outcome requires considering this 
possibility for the management of patients with both sporadic and hereditary BCC. In this 
article, an extensive review of the recent literature was made, in order to clarify the role of 
PDT as a possible alternative therapeutic option in the treatment of BCC. 








Basal cell carcinoma (BCC) is a very common malignancy, accounting for 80% of non-melanoma 
skin cancers (NMSCs) and affecting around two million people each year, with a steadily increasing 
incidence [1,2]. It develops mainly in subjects with fair skin and a history of chronic sun exposure,  
but certain categories of patients, such as solid organ transplant recipients and/or chronically 
immunosuppressed people, are most frequently affected. In addition, other risk factors include scars, 
exposure to arsenic, and hereditary disorders such as nevoid basal cell carcinoma syndrome (Gorlin-Goltz 
syndrome) and xeroderma pigmentosum [3]. The site of predilection is represented by chronically  
sun-exposed skin of the head and neck region, but multicentre superficial BCC frequently arise on the 
trunk. The median age at onset is over 60 years, even if diagnoses made in people younger than 40 years 
are progressively increasing [1]. Metastases from BCC are very rare, with an estimated incidence of 
0.0028%–0.55% [4]. However, the tumor is locally invasive and can infiltrate and destroy the 
subcutaneous tissue, bone and cartilage, reaching vital structures (major vessels or central nervous 
system); complications like bleeding and infections can affect the prognosis of patients, especially 
when elderly and debilitated [2]. 
Currently, multiple therapeutic options are available for the treatment of BCC, providing an 
excellent response rates in most of cases treated. However, the fact that the diagnosis of BCC is 
frequently carried out on patients with multiple comorbidities makes alternative minimally invasive 
procedures necessary. 
Photodynamic topical therapy (PDT) is a procedure based on the administration of a photo-sensibilizing 
agent, followed by irradiation at a pre-defined wavelength [5]. The creation of reactive oxygen species 
specifically destroys neoplastic cells, representing an effective treatment for certain types of skin 
cancers [6]. PDT is generally well tolerated, with minimal side effects, and this therapeutic option 
should be take into consideration for the treatment of BCC, if patients are properly selected [5,6]. 
This paper, starting from an extensive review of the literature related to the topic, describes the 
main treatment options currently available for the management of BCC, with particular attention to 
recent results on the use of PDT in this disease and on its potential benefits and possible limitations. 
2. Clinical and Histopathological Aspects of BCC 
2.1. Clinical Features 
BCC usually occurs as a single lesion, even if the appearance of simultaneous or subsequent lesions 
is a not infrequent event. 
Five main clinic types of BCC has been described [7–13]: 
i. Nodule-ulcerative BCC is the most common variant, accounting for almost 80% of cases and is 
represented by a small nodule with teleangectasic vessels on his surface [7–9]. The nodule 
progressively increases in size and often develops a central ulceration, surrounded by a pearly 
border; however, nodular BCCs are typically indolent and slow growing. 
ii. Invasive BCC (basalioma terebrans) is a rare variant that growth aggressively and can invade 
deep tissues and bone, destroying progressively structures as the nose or eyes [10]. 
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iii. Pigmented BCC shows clinical features similar to nodule-ulcerative BCC, but differs for the 
presence of brown or dark pigmentation. 
iv. Morpea-like or fibrosing BCC account for almost 6% of BCC and occurs mainly on the face; is 
represented by a flat or slightly depressed indurate plaque, with ill-defined borders and shows a 
more aggressive history, with frequent recurrences [7–9,11]. 
v. Superficial BCC account for up to 15% of cases and consists of a erythematous, slightly infiltrated 
patch, mainly located on the trunk, with a tendency to increase by a peripheral extension. Often 
there are a fine pearly border around the patch and small ulcerations on its surface [7,9,12,13]. 
2.2. Histopathological Features 
BCC is characterized by the presence of cells with a large, hyperchromic nucleus and scanty 
cytoplasm. The majority of BCCs are well demarcated and peripheral cells shows a palisade arrangement; 
however, areas of infiltrative growth can be present and fibrotic changes in the dermis could be  
a marker for more aggressive variants [14]. 
The stromal tissue is arranged in parallel bundles around the tumor masses and frequently there are 
areas of stromal retraction from the tumor islands, which result in peritumoral lacunae. The typical 
stroma of BCC is fibromyxoid, with presence of mucin, rare infiltrating lymphocytes and higher 
number of dilated vessels. These characteristics represent a useful diagnostic clue; moreover, the 
presence of stroma at the margin of the lesion suggests an incomplete tumor removal and represents an 
indication for re-excision [15]. Quantitative differences in the peritumoral stroma among BCC 
subtypes have also been demonstrated [16]. BCC is highly dependent to the surrounding stroma for 
survival; nonspecific inflammatory phenomena can disrupt this stroma and play an important role in 
tumor involvement, explaining the spontaneous or biopsy-induced regression of BCC that is 
occasionally reported [17]. 
As previously demonstrated by Roozeboom et al. [18], in BCCs with a maximum tumor thickness 
of 1.0 mm, histologic characteristics, tumor thickness and adnexal extension are not associated  
with treatment failure. However, tumour biopsy is recommended in order to avoid a clinical 
underestimation of the BCC thickness that may result in a treatment failure [19]. 
Conversely, the Fiechter’s retrospective histopathological analysis [20] of BCCs recurring after 
methyl aminolevulinate (MAL)-PDT provides evidence that 62.5% of the superficial or nodular 
primary BCCs show a relapse characterized by a more aggressive histological pattern. Although the 
latter may reflect the natural course of tumor, their data suggest that BCCs recurring after PDT show 
an as yet unrecognized risk of behaving more aggressively [21]. Some BCC cells that have received a 
sublethal dose of PDT could accumulate enough DNA damage to behave more aggressively. 
3. Conventional Treatment of Localized BCC 
Conventional therapies for the treatment of the BCC are many, and the choice between different 
options should take into account both age and comorbidities affecting the patient and clinical and 
histopathological features of the lesion to be treated [22]. Superficial and nodular BCC are usually 
considered at lower risk of recurrence, whereas this is increased for infiltrative and micronodular 
subtypes. Lesions that develop in sensitive anatomic areas, such as face, extremities and genitalia and 
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those measuring more than 2 cm in diameter are classified as high-risk [23–25]. Indeed, BCCs can be 
classified as low- or high-risk lesions also on the basis of others factors, including the presence of 
well-defined vs. ill-defined borders, the presence or absence of perineural invasion, recurrent vs. 
primary disease, previous radiotherapy and immunosuppression status [22]. 
3.1. Surgery 
The first treatment choice for BCC management is represented by surgery, given a relatively low 
rate of recurrence and the possibility to have a histological control of the tumor. However, there are 
several disadvantages, represented by the usual operative risks, aesthetically or functionally disturbing 
scars and pigment changes, as well as possible delays in wound healing [26]. The goal of the treatment 
is represented by the tumor eradication with the minimal destruction of the tissue in order to preserve 
the function and the appearance. So, the choice between the different surgical options should be 
determined on the basis of the possible presence of risk factors in the tumor to be treated. 
Curettage with electrodessication, and surgical excision with postoperative margins control are 
considered the first-rate treatments for low-risk BCCs [22], giving a five-year overall cure rate of 92% 
and 98%, respectively [27–29]. However, Mohs surgery is the treatment of choice in all high-risk lesions 
and for BCC localized on eyes, lips or nose, with a five-year disease free survival rate of 99% [2,26,30]. 
3.2. Liquid Nitrogen Cryotherapy and Ablative Laser Therapy 
Cryotherapy obtains destruction of the neoplastic tissue by low temperature freezing. The rationale 
is based on the fact that the high water content, high metabolism and high number of blood vessels 
make neoplastic cells more sensitive to low temperature [31]. Moreover, the benefits of this therapy 
include its ability to trigger a specific T lymphocyte response and to increase the activity of natural 
killer cells by releasing tumor antigens and inflammatory mediators. 
Cryotherapy is simple and money saving and is commonly applied to the treatment of NMSC 
precursors. However, it can also be occasionally used in superficial or small-size BCCs [26,31]; two 
randomized controlled trials showed cure rates ranging from 85% to 95% [32,33]. Side effects develop 
in 20%–50% of patients and include pain, erythema, blisters and crusts. The main disadvantages of this 
procedure are represented by hypopigmentation or scarring, and by the lack of histological control [32]. 
Similar problems are observed with ablative laser treatment, that is usually performed with CO2 or 
Erbium YAG laser. 
3.3. Topical Treatment Strategies 
The cytostatic agent 5-fluorouracil (5-FU) is available as a 5% cream that is designed for twice 
daily application for 3–12 weeks until erosions develop. The 5-FU is a chemotherapic agent that 
interferes with DNA synthesis by inhibiting thymidylate synthetase, thus decreasing cell proliferation; 
as a final effect cellular apoptosis is obtained. The experience on the use of 5-FU to treat BCC is well 
established. In fact, since the seventies, several studies [34–36] demonstrated the effectiveness of 5-FU 
in more than 80% of superficial BCCs. A more recent study on 31 BCCs demonstrated that the use of 
twice-daily 5-FU for an average of 11 weeks might lead to a 90% histologic cure rate [37]. A large 
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multicenter single-blinded randomized comparative trial [38] reported instead a cure rate of 80%. 
Advantages of topical 5-fluorouracil are scar-free healing and the possibility to treat wider areas. 
Disadvantages are the sometimes severe inflammatory and erosive reactions, which develop at 
individually variable time intervals (days to weeks) and the dependence on good patient compliance. 
Topical imiquimod binds the toll-like receptor 7 and provides immunomodulatory effects by 
increasing the release of pro-inflammatory cytokines; it is currently approved for the treatment of 
small superficial BCC, with a complete cure rate around the 80% [39,40]. Due to the fact that tumour 
thickness is considered as a predictor of response in patients treated with imiquimod [41–43], reports about 
successful treatment of large BCC are rare. Indeed, few cases of giant tumors cured without pathological 
evidence of recurrences after a long-term follow-up have been reported [44]. Reported adverse events 
are erythema, flaking, blistering, erosions and ulceration; most of them resolve after eight weeks [45]. 
Recently, the Food and Drug Administration (FDA) approved ingenol mebutate (the active principle 
extracted from the sap of Euphorbia peplus) [46] for the treatment of precancerous lesions. Few cases 
of home treatment of NMSC with the sap of Euphorbia peplus are reported by literature [46,47] and 
experimental studies suggested a possible role of ingenol mebutate also for BCC patients who failed or 
were ineligible for conventional treatments [48,49]. For patients affected by BCC, the complete 
clinical response after one month was 82%, whereas after a mean follow-up of 15 months, the response 
rate was 57%. In another phase II trial [48], a histologically confirmed clearance of the treated lesions 
occurred in 65% of the patients; efficacy appeared to be dose-dependent and significantly higher in 
patients treated for two consecutive days. 
3.4. Radiotherapy 
Radiotherapy may be considered when the tumor site or size prevents surgical approach, or when 
the patient's medical history contraindicates other types of treatment. Other indications are represented 
by incomplete surgical excision or relapses, when re-intervention is not technically feasible [26].  
The S2-K guidelines recommend high-energy radiation therapy (electron or photon beam); primary 
tumors are treated with daily doses of 2–3 Gy and a total dose of 60–70 Gy. After R1 resection, 50–60 Gy 
are recommended and after R2 resection, 60–70 Gy [2]. Large tumors or those in unfavorable locations 
can be treated by intensity-modulated radiation therapy or tomotherapy [50,51]. 
Large retrospective studies reported a five-year overall response varying between 88.6% and 96.1%, 
according to the size of the neoplasia [26,52,53]. 
4. PDT in the Treatment of Localized BCC 
4.1. Background 
PDT is a clinically approved, minimally invasive therapeutic procedure with a selective cytotoxic 
activity, which is successfully used for the management of neoplastic and non-malignant diseases [5]. 
PDT requires three essential components: a photosensitizer, a light source, and oxygen. When the 
photosensitizer is exposed to specific wavelengths, it becomes active from a “ground state” to an 
“excited state”; as it returns to the ground state, the energy released can mediate selective cell killing [6]. 
The selectivity of the photosensitizer uptake and the duration and depth of the light source minimize 
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the damage to surrounding healthy tissue; in fact, PDT has a low potential for causing DNA damage, 
mutation, or carcinogenesis [54]. 
There are many types of photosensitizers available and several routes (topical, oral, or intravenous) 
by which they can be delivered to the patient. Currently, the only photosensitizers approved for 
dermatologic indications are aminolevulinic acid (ALA) and methyl aminolevulinate (MAL); both are 
prodrugs that require conversion to photo-activable porphyrin [55]. ALA crosses the cell membrane, 
and conversion to prothoporpirin IX (PpIX) occurs inside the cell. However ALA-esters, such as 
MAL, are first hydrolyzed to ALA in the cytosol [56]. 
Additional factors also affect the efficiency of PpIX production and higher temperatures facilitate 
conversion [57]. 
ALA has low lipid solubility, limiting its ability to penetrate through skin (no deeper than 2 mm) or 
cell membranes and thus restricting its use in PDT to superficial diseases [58]. MAL is reported to 
have increased lipophilicity and deeper skin penetration when compared with ALA [59]. 
In vivo and ex vivo imaging results demonstrate the potential of Vitamin D as a combination treatment 
to enhance ALA induced PpIX synthesis, resulting in higher tumor cell death following PDT [60]. 
4.2. Patient Selection and Technical Aspects 
PDT is generally recommended as a treatment option for superficial and thin nodular BCC 
(thickness < 2 mm). However, some investigators accept 2–3 mm thick BCC for PDT when combined 
with a previous lesion curettage. In fact, the main barrier to the absorption of photosensitizers is the 
stratum corneum [61] and preparatory steps are necessary to improve photosensitizer uptake [62]. 
Some practitioners have observed reduced efficacy if lesions are not debrided prior to PDT [63]. 
Occlusion of lesions with a keratolytic the night before treatment can facilitate crust removal.  
Tape-stripping, microdermabrasion, laser ablation or gentle curettage can also be used to reduce 
hyperkeratosis [57,62–67]. 
Christensen et al. [18] demonstrated that the mean reduction of tumor thickness after deep curettage 
was 50% and was independent from the histological subtype. So, even if curettage before topical PDT 
may significantly improve complete clearance rate, results obtained in nodular subtypes remain scanty. 
Treatment of scalp lesions need to be particularly careful, and might also be more difficult due to 
the presence of hair. Cutting hair before treatment can be helpful to localize the extension of the lesions. 
4.3. Clinical Results 
4.3.1. ALA-PDT in Treatment of BCC 
The main studies recently published about the use of ALA-PDT in treatment of BCC are reported in 
Table 1. 
A 10-year longitudinal study performed on 60 lesions found that the complete response (CR) rate 
for primary lesions after superficial curettage was 78%, with 63% after one session and 90% after two 
sessions. This study used ALA-PDT with halogen light (light intensity 150–230 mW/cm2). The cosmetics 
outcome was rated as good or excellent in over 91% of the evaluated cases [68]. Another study (n = 94) 
compared the CR rate (mean follow-up 25 months) for sBCC in patients who received ALA-PDT 
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(31/31, 100%) vs. surgery (28/29, 96.55%). Patients with nBCC had better response rates with surgery 
(16/17, 94.12%; p = 0.88) than those treated with ALA-PDT (15/17, 88.24%) [69]. Wang et al. [70] 
demonstrated that the efficacy of ALA-PDT is similar to that of cryosurgery, with the advantage of 
greater cosmetic results, achieved in a lesser healing interval. 
A study published in 2012 by Osiecka and colleagues [71] evaluates the use of combined therapy 
encompassing both ALA-PDT and imiquimod 5% on a group of 34 patients that were randomized 
between ALA-PDT combined with vehicle placebo cream (n = 10 patients) and ALA-PDT combined 
with topical applications of imiquimod (n = 24 patients); the authors encountered a complete remission 
in 60% of the patients from the first group, compared to 75% in the second group [71]. 
ALA-PDT does not seem to be an efficient option for the treatment of nodular forms. In the largest 
single institution experience with 1440 nodular and superficial BCCs, PDT shows an initial CR rate  
of 92%. However, the response rate dropped to 71% in 75 patients with nodular BCC [72]. Moreover, 
a controlled randomized study enrolling 149 patients with 173 BCCs, surgically excised with safety 
margins of 3 mm or treated with ALA-PDT, proved a 3-years recurrence rate of 2.3% for the surgical 
excision, compared to 30.3% for PDT [73]. 
Table 1. Clinical results of ALA-PDT in treatment of BCC. 
Authors 
No. of Treated 
Lesions 
Histotype Treatment Outcome 
Follow-up 
(Months) 
Zeitouni et al., 2001 [72] 
1440 sBCC/nBCC CR 92% 6 
75 nBCC CR 71% NA 
Mosterd et al., 2008 [73] 173 (149 pts) BCC CR 69.7% 36 
Christensen et al., 2012 [68] 60 BCC CR 78% 120 
Osiecka et al., 2012 [71] 34 BCC 
CR 60% (ALA-PDT + placebo) 
 CR 75%  
(ALA-PDT + imiquimod) 
Cosgarea et al., 2013 [69] 94 
sBCC CR 100% 
25 
nBCC CR 88.24% 
CR: complete remission; NA: not available. 
4.3.2. MAL-PDT in the Treatment of BCC 
MAL-PDT is a very safe and efficient therapeutic approach, mainly for patients with superficial 
variants of BCC, as demonstrated in the majority of published series. The main studies recently 
published about this topic are reported in Table 2. In 2001, Soler et al. [74] published a study on  
350 superficial BCCs and previously curetted nodular BCCs, on which 160 mg/g concentration MAL 
was applied 3 h before illumination with a PDT lamp. At the end of the study, 310 of the 350 treated 
lesions remitted completely, 89% of them maintaining the remission even after three years.  
The cosmetic results were reported as good or excellent in 98% of the cases that achieved complete 
remission [74]. In another study published in 2011 [75] Fantini et al. reported an overall response rate 
of 62%, varying from 82% for sBCC and 33% for nBCCs. The study proved that both limb location of 
BCCs and the presence of ulceration negatively affect the efficacy of MAL-PDT whereas the size of 
the lesions does not seem to influence the outcome of the procedure. 
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Also for MAL-PDT, the efficacy of the technique is inversely related to the thickening of the lesion, 
as consequence of the physical ability of the luminous radiation to penetrate the skin. A study 
conducted on 95 BCCs of different thickness, stratified the results depending on the thickness of the 
lesion, as it follows: CR in lesions with thickness less than 1.3 mm, partial response in lesions between 
1.3 and 1.8 mm and lack of response in those that exceeded 1.8 mm in thickness, with a two-year 
overall response rate of 75.8% [76]. 
Two randomized, multicenter, double-blind trials performed in Australia support the efficiency of 
MAL-PDT in the treatment of nodular BCC. The trials enrolled 131 patients, 66 of whom were 
referred for MAL-PDT treatment and 65 were treated with placebo-PDT. A histologically confirmed 
complete remission was observed in 75% of patient treated with MAL-PDT and only in 27% in the 
group treated with placebo-PDT [77]. MAL-PDT is reported also as adjunctive therapy for 
sclerodermiform BCC prior to standard surgical excision in order to reduce tumor size [78] and may be 
also considered for pigmented BCCs after an adequate debulking; however, patients should be closely 
followed due to higher recurrence risks [79]. 
MAL-PDT is also efficient for BCCs that are considered “difficult to treat” in respect to their 
dimensions or topographic location or to patient general clinical condition. An open, prospective, 
uncontrolled study assessed 94 patients with 123 “difficult to treat” BCC, with a remission rate of 92% 
for superficial BCC and 87% for the nodular ones [80]. Similar encouraging results were obtained also 
in the treatment of BCC of the eyelid margin [81,82]. On the contrary, lesions in the H-zone have 
reduced clearance rates. 
Table 2. Clinical results of MAL-PDT in treatment of BCC. 
Authors 
No. of Treated 
Lesions 
Hystotype Treatment Outcome 
Follow-up 
(Months) 
Soler et al., 2001 [74] 350 sBCC/nBCC CR 88.57% 36 
Horn et al., 2003 [80] 123 (94 pts) 
sBCCs CR 92% 
24 
nBCCs CR 87% 
Foley et al., 2006 [77] 131 BCC 
CR 75% (MAL-PDT) 
NA 
CR 27% (PDT + placebo) 
Eibenschutz et al., 2008 [83] 
14 < 50 mm 
BCC 
CR 95% 6 
40–49 mm CR 66% 36 
Li et al., 2010 [76] 95 (47 pts) sBCC OR 75.8% 24 
Fantini et al., 2011 [75] 194 (135 pts) 
 OR 62%  
sBCC CR 82% 
NA 
nBCC CR 33% 
CR: complete remission; OR: overall response; NA: not available. 
MAL-PDT also proves good results in treating giant BCC. Eibenschutz et al. [83] presented a series 
of giant and large BCC, showing a 95% remission rate after six months; three years post-therapy, the 
remission rate was maintained at 66% of the treated cases. The association of MAL-PDT with topical 
imiquimod leads to a considerable reduction in the tumoral dimensions, allowing a subsequent 
excision to be performed in safe conditions [84]. 
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4.4. Side Effects and Follow-up 
Throughout, PDT is a well tolerated and a relatively cost-sparing technique. Absolute contraindications 
to PDT include history of porphyria, systemic lupus erythematosus or other photosensitive dermatoses, 
and allergy to the active ingredients in the photosensitizer, which is considerably rare. 
Common side effects of this technique include erythema, edema, itching, epithelial exfoliation, 
pustules, and post-inflammatory hyperpigmentation, especially for Fitzpatrick skin phototype IV–V [85]. 
The most common reaction is represented by pain during administration [86], especially in patients 
treated with ALA, as demonstrated in comparative studies with MAL-PDT [87]. 
The recommended PDT treatment schedule for BCC in the majority of European countries is 
represented by two session at baseline, one week apart, with a re-evaluation after three months and a 
second cycle if necessary. In doubtful cases, the clinical evaluation may be supported by a biopsy to 
confirm the successful remission of the lesion; till now only few reports are available concerning the 
utility of dermoscopy in the assessment of lesions after PDT or other non-ablative therapies [88]. 
5. The “Nevoid Basal Cell Syndrome” (Gorlin-Goltz Syndrome) 
5.1. Clinical Features 
The nevoid basal cell syndrome is an autosomal dominant disorder with a low penetration that was 
described for the first time by Gorlin and Goltz in 1960 [89,90]. In Europe, the approximate prevalence 
of this syndrome is reported to be 1 in 30,827 (England) to 1 in 256,000 (Italy). More recently, the 
gene responsible for Gorlin-Goltz syndrome has been identified as PTCH1, which encodes the receptor 
for Sonic hedgehog protein [91,92]. Because the hedgehog-signaling pathway plays a pivotal role in 
embryonic development and tumor genesis, its deregulation results in various developmental defects 
and tumors. The patients affected by Gorlin-Goltz syndrome suffer since puberty with hundreds of 
small BCCs that increase progressively in number and size and are distributed randomly over the entire 
face or body. During adulthood, tumors became progressively invasive and can cause significant tissue 
destruction [93]. Patients affected by Gorlin-Goltz syndrome often show numerous palmo-plantar pits, 
epidermal cysts and different skeletal and central nervous system abnormalities. Moreover, they are 
more prone to develop various tumors, as medulloblastoma, ovary carcinoma, cardiac fibroma and 
odontogenic tumors [90]. 
5.2. Treatment 
No guidelines exist for the treatment of Gorlin-Goltz syndrome. Since this condition is chronic and 
patients will continue to develop new lesions throughout their life, the goal of treatment is not 
necessarily complete remission [94]. Radiotherapy is contraindicated in these patients because it may 
induce new BCCs [95]. Lesion response rate to imiquimod, 5-FU and cryotherapy for sBCC in  
Gorlin-Goltz is variable. 
Gorlin-Goltz patients have numerous lesions, so it is preferable to treat an entire area with field 
therapy rather than a single lesion approach; MAL-PDT can be considered and may lead to a potential 
reduction in surgical procedures. Although MAL-PDT is not approved for children, pediatric patients 
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with Gorlin-Goltz might also be evaluated for this therapy. A recent case report also suggested a 
chemo preventive role of PDT in a patient with Gorlin-Goltz syndrome [96]. 
6. Treatment of Advanced BCC 
Until a few years ago, the therapeutic approach for patients with locally advanced or metastatic 
NMSCs was exclusively represented by conventional chemotherapy, based on platinum, taxanes, or 
combinations of 13 cis-retinoic acid and interferon-alfa [35]. The remission rate reached by these 
therapies was low and serious side effects were frequent.  
The above-mentioned recent identification of PTCH1 mutations in BCC led to the development of 
the hedgehog (SMO) inhibitor vismodegib, that demonstrated a more specific antitumor activity and 
less toxicity than conventional drugs [97] and was approved by the FDA in January 2012 and by the 
European Medicines Agency (EMA) in July 2013. The administration of vismodegib 150 mg daily 
showed a response rate of 58% with a median duration of 12.8 months in a Phase I study involving  
33 patients with advanced BCCs [98]. These encouraging results were confirmed by other multicentric 
studies that enrolled patients with advanced, inoperable or metastatic BCCs [97,99]. Preliminary 
promising data were also reported for the prevention and treatment of BCCs in patients with the basal 
cell nevus syndrome but a Phase III study is still ongoing. 
Hedgehog pathway inhibitors are markedly teratogenic and embryotoxic, on the other hand 
vismodegib is quite-well tolerated, with specific mechanism-related side effects, including muscle 
spasms, alopecia, dysgeusia, weight loss, and fatigue [97]. However, a crucial point that needs further 
investigations is represented by the development of resistance to vismodegib during long treatments, 
probably due to the onset of new mutations in SMO [98]. 
Recently, the Committee for Medicinal Products for Human Use (CHMP) has given a favorable 
opinion to sonidegib, and several studies about other new SMO inhibitors are ongoing [97–99] both on 
advanced BCC and on other solid tumors. 
7. Future Perspectives in BCC Treatment 
Daylight photodynamic therapy (DL-PDT) is a promising treatment for multiple grade I and II 
actinic keratosis on the face and scalp; this type of treatment was approved in 2014 in Australia, Brazil 
and Colombia but not yet in European countries [100]. Daylight photodynamic therapy using MAL has 
also been used in an exploratory study of 21 patients with 32 BCCs who received two treatments one 
week apart, achieving a 90% three month complete clinical response rate; however six patients 
recurred during a 12 months follow-up [101]. 
Nanotechnology has been explored as a novel platform for cancer treatment, with a potential role 
also in skin tumors, even if today data about its specific application to BCC are not available. 
Nanocarriers for drugs have the potential to enhance the therapeutic efficacy of a drug, since they can 
be engineered to modulate its release and stability, and to prolong its circulation time, protecting it 
from elimination by phagocytic cells or premature degradation. Moreover, nanoscale carriers can be 
tailored to accumulate in tumor cells and tissues, both through the enhanced permeability and retention 
effect, and by active targeting strategies using ligands designed to recognize tumor-associated 
molecular markers [102,103]. 
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Nanoparticles may be used as a base for the construction of multifunctional nanoscale devices. 
These devices offer the opportunity to combine diagnostic, imaging or targeting agents with 
therapeutic agents in the same package. Thus far, several kinds of nanoparticles have been engineered 
and used in PDT applications; these nanoparticle agents range from liposomes, oil-based dispersions, 
polymeric particles and hydrophilic polymer–photosensitizer conjugates to gold nanoparticles. The 
porous structure of silica nanoparticles can not only act as a suitable carrier for hydrophobic 
photosensitizers, but also allow the oxygen and generated permeability that is essential for PDT [104]. 
8. Conclusions 
Surgical excision is still the first choice for treatment of BCC, but when surgery is infeasible due to 
tumor size or location or patient clinical characteristics or when it is necessary to take into 
consideration the cosmetic outcome, PDT should be considered as a good treatment option. 
Differences in photosensitizers, patient preparation, and proper total amount of light irradiation or 
number of PDT cycles may result in different treatment outcome. However, no significant differences 
in recurrence rates of PDT-treated BCC were found between immunocompetent or solid organ 
transplanted patients [105], demonstrating the feasibility of this technique also in those patients in 
which others therapeutics approach cannot be used. 
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